Physician profile
Chrystal Doyle
NPI 1669031191
$2,921.70
in general payments reported to CMS, 2019-2025
20 companies · $1,547 in 2025
The $1,547 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $424 · 2022: $510 · 2024: $440 · 2025: $1,547.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,987.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,986.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $602.44 | 2021-2025 | |
| Novo Nordisk INC | $323.94 | 2021-2022 | |
| Alkermes, INC. | $231.93 | 2025 | Lybalvi |
| Sandoz INC. | $162.69 | 2025 | |
| Axsome Therapeutics, INC. | $136.34 | 2025 | Auvelity |
| Teva Pharmaceuticals USA, INC. | $124.74 | 2024 | Austedo Xr |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $124.73 | 2025 | Xifaxan |
| Biohaven Pharmaceuticals, INC. | $122.55 | 2021 | |
| Eisai INC. | $121.96 | 2025 | |
| Lilly USA, LLC | $119.60 | 2025 | Mounjaro |
| E.R. Squibb & Sons, L.L.C. | $118.76 | 2025 | Cobenfy |
| Antares Pharma, INC. | $115.10 | 2022 | |
| Paratek Pharmaceuticals, INC. | $108.87 | 2022 | |
| Pfizer INC. | $104.60 | 2025 | |
| Biogen, INC. | $84.05 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $81.73 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $73.64 | 2024 | Abilify Maintena, Abilify Asimtufii |
| Genzyme Corporation | $64.96 | 2025 | |
| Janssen Pharmaceuticals, INC | $63.74 | 2025 | Spravato |
| Bard Peripheral Vascular, INC. | $35.33 | 2025 | Venclose Maven Catheter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chrystal Doyle listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.